So I've been looking at Globus Medical lately and there's actually something interesting happening in the med device space that caught my attention. The company's been quietly gaining serious ground in musculoskeletal solutions, which is a pretty solid niche if you ask me.

What's got me watching this is their execution. Since they integrated NuVasive, Globus has been pumping out new products at a pace that actually matters. We're talking about launches like the ANTHEM Elbow Fracture System last October and DuraPro with Navigation in July. That's not just noise - that's consistent innovation that's actually moving the needle in their core spine business, which grew 10% year over year in Q4. Their trauma business? Up 27% in the same quarter. That kind of momentum doesn't happen by accident.

The financial position is solid too. Globus finished Q4 2025 with 526 million in cash and zero short-term debt. No long-term debt either. In this macro environment, that's actually pretty rare and gives them real flexibility to keep investing in product development.

Now, the reality check: macroeconomic headwinds are real. We're dealing with interest rate swings, inflation that's still sticky, and supply chain complexity. Globus saw SG&A expenses jump 25.8% year over year in Q4, which is the kind of thing that keeps management up at night. The consensus is pricing in 8% revenue growth for 2026 to around 3.17 billion, which seems reasonable but not spectacular.

Here's the thing though - Globus has been beating earnings estimates consistently. Three out of the last four quarters they came in ahead with an average surprise of 18.8%. The earnings yield sits at 4.7% versus the industry average of 0.8%, which tells you the market hasn't fully priced in what this company's actually doing.

I'm not saying it's a slam dunk. The medical device space has competitive pressures and macro uncertainty is real. But if you're looking at the musculoskeletal solutions market and how Globus is positioned, there's a legitimate case for why this could be worth adding to a portfolio. The stock ran up 14.7% over the past year while the S&P was up 19.3%, so it's not like everyone's already piled in. Worth keeping on the radar if you're hunting for exposure to this sector.